Long-term Insulin vs Liraglutide Effect on Beta-cell Function in Type 1 Diabetes with Residual Insulin Secretion-Extension Study

Long-term Insulin vs Liraglutide Effect on Beta-cell Function in Type 1 Diabetes with Residual Insulin Secretion-Extension Study - SAVE-ISLET Extension Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006990

Enrollment

Registered

2011-12-30

Start date

2011-12-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 diabetes with residual insulin secretion (Slowly Progressive Insulin-Dependent Diabetes millitus, Latent Autoimmune Diabetes in Adults)

Interventions

Liraglutide group Continuous administration of Liraglutide injection 0.6-0.9mg per day on insulin therapy for 52 weeks (Totally 108 weeks) Liraglutide group Insulin group Additional administratio

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. The patients who have agreed to participate in this study with an informed consent 2. The patients who have finished the previous study

Exclusion criteria

Exclusion criteria: 1. The patients who did not agree with this study 2. The patients who was observed a serious complication in previous study 3. Those who are not approved to be eligible to this study by corresponding researcher or co-researchers

Design outcomes

Primary

Measure	Time frame
Changes in insulin secretory response to glucagon- and arginine-stimulation test	—

Secondary

Measure	Time frame
Anti GADAb, Glycemic control(HbA1c, FPG/PPG, 7 points blood glucose levels in self-monitoring of blood glucose, Body weight, Hypoglycemia, Total dose of insulin injection per day, Adverse Events (including an abnormal laboratory finding)	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026